Virtu Pharmako

Virtu Pharmako Co. Ltd.（Virtu Pharmako）is a biopharmaceutical company with an original technology platform and mature industrialization capabilities. The company was founded in 2021 by Dr. Fan, Hao, who has developed a cutting-edge proprietary prokaryotic technology platform that utilizes prokaryotic organisms, i.e. Escherichia coli (E. coli), for efficient and highly scalable manufacture of recombinant proteins.

Virtu’s pipeline includes Insulins & GLP-1s, both API & finished products, as well as various other biopharmaceuticals and tool enzymes, covering more than one-third of the categories of biopharmaceuticals and biological products.
Completed the construction of a manufacture site in 2025, with an annual capacity of 3 tons of biopharmaceutical APIs and 140 million finished dosage forms.

Virtu’s huge production capacity also enables the provision of CRO/CMO services, encompassing biopharmaceutical development and fill-finish manufacturing of formulations.